Neuroendocrine Tumors Treatment Market Size, Share and Forecast 2026
The Neuroendocrine Tumors Treatment Market was worth $XX million in 2018 and is forecasted to reach $XX million by 2026, at a CAGR of XX% during the forecast period.
(EMAILWIRE.COM, September 16, 2019 ) Market Overview:
Neuroendocrine tumors (NETs) are caused by abnormal growth of neoplasms that originate from hormone-producing cells of endocrine glands and nervous systems. NETs may develop anywhere in the body, such as intestines, stomach, pancreas, and lungs, that makes diagnosis difficult at early stages. NETS are a rare malignant disorder that accounts for only around 1% of all malignant disorders. NETs can be either symptomatic or asymptomatic. They generally affect intestine and pancreas.
The treatment adopted for NETs focuses on controlling underlying symptoms and complications related to the progression of the disease. Treatment options include surgery, radiation therapy, and chemotherapy.
Market Dynamics:
The market is driven by increased cases of NETs, heavy investment by various pharmaceutical companies for clinical trials of novel products, technological advancements in therapies, robust pipeline and increased funding by many government and non-government organizations. Lack of skilled healthcare professionals and lower adoption of advanced treatment technologies are going to restrain the market in the forecast period.
Market Segmentation:
By Treatment Type
• Surgery
• Drug Therapies
• Interventional Radiology
By Treatment Site
• Gastrointestinal
• Pancreas
• Lung
• Others
Geographical Analysis:
By Geography, the market is segmented into:
• North America
• Europe
• South America
• Asia Pacific
• The Middle East and Africa
Competitive Analysis:
Key Players:
• Pfizer, Inc.*
• Novartis AG
• Ipsen Pharma
• Dauntless Pharmaceuticals, Inc.
• Exelixis, Inc.
• Hutchinson
• Others
View full report: https://www.datamintelligence.com/research-report/neuroendocrine-tumors-treatment-market
Download free sample: https://www.datamintelligence.com/download-sample/neuroendocrine-tumors-treatment-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Neuroendocrine tumors (NETs) are caused by abnormal growth of neoplasms that originate from hormone-producing cells of endocrine glands and nervous systems. NETs may develop anywhere in the body, such as intestines, stomach, pancreas, and lungs, that makes diagnosis difficult at early stages. NETS are a rare malignant disorder that accounts for only around 1% of all malignant disorders. NETs can be either symptomatic or asymptomatic. They generally affect intestine and pancreas.
The treatment adopted for NETs focuses on controlling underlying symptoms and complications related to the progression of the disease. Treatment options include surgery, radiation therapy, and chemotherapy.
Market Dynamics:
The market is driven by increased cases of NETs, heavy investment by various pharmaceutical companies for clinical trials of novel products, technological advancements in therapies, robust pipeline and increased funding by many government and non-government organizations. Lack of skilled healthcare professionals and lower adoption of advanced treatment technologies are going to restrain the market in the forecast period.
Market Segmentation:
By Treatment Type
• Surgery
• Drug Therapies
• Interventional Radiology
By Treatment Site
• Gastrointestinal
• Pancreas
• Lung
• Others
Geographical Analysis:
By Geography, the market is segmented into:
• North America
• Europe
• South America
• Asia Pacific
• The Middle East and Africa
Competitive Analysis:
Key Players:
• Pfizer, Inc.*
• Novartis AG
• Ipsen Pharma
• Dauntless Pharmaceuticals, Inc.
• Exelixis, Inc.
• Hutchinson
• Others
View full report: https://www.datamintelligence.com/research-report/neuroendocrine-tumors-treatment-market
Download free sample: https://www.datamintelligence.com/download-sample/neuroendocrine-tumors-treatment-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results